Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Trial SOUL (McGuire et al., NEJM 2025) Design Phase 3 / event-driven Population Adults with T2D + ASCVD or CKD Key result Oral semaglutide significantly reduced MACE vs placebo in high-CV-risk T2D
Citrus, coffee, or chocolate flavors are effective
CagriSema produced ~22.7% weight loss (vs
However: More than three-quarters of this spending growth was due to the growth in utilizationthe number of people being treated and the number of prescriptions being dispensed
A DEXA scan measures fat mass, lean mass, visceral fat, and bone densityproviding context that a scale alone cannot
US$ 28.90
US$ 25.79
US$ 20.76
US$ 27.50
